Monoclonal Gammopathy of Undetermined Significance Clinical Trials
2 recruiting trials for Monoclonal Gammopathy of Undetermined Significance. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Monoclonal Gammopathy of Undetermined Significance clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1), Fondazione IRCCS Policlinico San Matteo di Pavia (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Whole Body-Magnetic Resonance Imaging (WB-MRI) (diagnostic_test, 1 trial), followed by no intervention.
Track Monoclonal Gammopathy of Undetermined Significance trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Whole Body MRI in Oncology
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in...
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1....
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Monoclonal Gammopathy of Undetermined Significance, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Monoclonal Gammopathy of Undetermined Significance, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Monoclonal Gammopathy of Undetermined Significance, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.